Change-sensitive Measurement of Emotion Dysregulation in ASD

ASD 情绪失调的变化敏感测量

基本信息

批准号：
9276754
负责人：
Carla A Mazefsky
金额：
$ 44.95万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-10 至 2019-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9276754
关键词：
Achievement Address Admission activity Affect Aggressive behavior Anxiety Area Attention Autistic Disorder Award Behavior Calibration Caregiver Burden Caregivers Child Clinical Clinical Trials Cognitive Communities Comorbidity Data Collection Data Set Depressed mood Development Dimensions Emotional Emotions Equipment and supply inventories Evaluation Evidence based treatment FDA approved Factor Analysis Genetic Gold Guidelines Heterogeneity Hospitalization Hyperactive behavior Impairment Individual Information Systems Inpatients Interview Lead Life Measurement Measures Mental Depression Mental disorders Modeling Online Systems Outcome Measure Outcome Study Outpatients Output Parents Participant Patient Outcomes Assessments Persons Pharmaceutical Preparations Phenotype Population Population Study Problem behavior Process Property Provider Psychiatric Diagnosis Psychiatric therapeutic procedure Psychometrics Psychopathology Recording of previous events Regulation Research Sampling Severities Source Structure Symptoms Testing Time autism spectrum disorder base behavior observation emotion dysregulation emotion regulation emotional distress externalizing behavior innovation instrument literacy neuroimaging primary outcome psychiatric symptom public health relevance response stereotypy theories treatment effect treatment planning user-friendly young adult

项目摘要

DESCRIPTION (provided by applicant): Individuals with autism spectrum disorder (ASD) are often in need of psychiatric care due to poor emotion regulation and emotional distress. Only two psychotropic medications have been approved for use in ASD, both to treat irritability expressed as tantrums, outbursts, and aggression. However, the underlying deficits in emotion regulation that lead to these problem behaviors are poorly understood and rarely measured or targeted in treatment. Evidence-based treatment approaches for the full range of emotion dysregulation (e.g. depression, outbursts, meltdowns, etc.) present in ASD do not exist. A major barrier to progress in this area is a lack of validated, treatment sensitive measures of emotional distress for individuals with ASD. This project proposes to refine and validate a new measure of emotional distress and emotion regulation for ASD, called the Emotion Dysregulation Inventory (EDI). Guidelines from the Patient-Reported Outcome Measurement Information System (PROMIS) Project and gold-standard statistical approaches will be utilized to complete calibration and psychometric analysis of the EDI. The primary sample will include caregivers of 1000 children and young adults with ASD from community, outpatient, and psychiatric inpatient settings. Data collection will occur through an online system. Analyses will focus on establishing the EDI's factor structure/dimensionality, developing a less than 10-item short form, establishing convergent and divergent validity, comparing EDI scores among groups whose scores would be expected to differ (e.g. inpatients versus community sample; ASD versus healthy controls), and comparing EDI scores to observational counts of emotion dysregulation episodes displayed by children who are inpatients on two specialized psychiatric units. A subset of the sample will complete the EDI twice to establish test-retest reliability. The EDI's ability to detect treatment change will be determined by comparing both caregiver- and provider-rated EDI scores at admission and discharge across two psychiatric inpatient units that specialize in ASD and 4-week change scores in a stable community sample. The primary outcome of this study will be a user-friendly (e.g. available online, brief), validated, treatment sensitive outcome measure for clinical trials in ASD that is independent of verbal ability. In addition, this study will produce he largest existing dataset on emotion dysregulation in ASD, which will be used to identify emotional profiles and treatment needs in this population. Additional time-course questions in the EDI that tap the individual's history of emotion dysregulation will be useful for clinical conceptualization and helping to understand the boundaries between emotion dysregulation that is inherent in ASD and comorbid psychiatric disorders. Finally, having a sensitive measure of emotion dysregulation in ASD will aid in understanding heterogeneity in genetic and neuroimaging research and will enable cross-population studies

描述（由申请人提供）：由于情绪调节和情绪困扰，自闭症谱系障碍（ASD）通常需要精神病护理。仅批准了两种精神药物用于ASD，既可以治疗以发脾气，爆发和侵略性表示的烦恼。但是，导致这些问题行为的情绪调节的潜在缺陷对治疗的理解很少，很少被衡量或针对。不存在ASD中存在的全部情绪失调（例如抑郁症，爆发，崩溃等）的循证治疗方法。该领域进步的主要障碍是缺乏对ASD患者的验证，治疗敏感的情绪困扰措施。该项目建议对ASD的情绪困扰和情绪调节进行完善和验证，称为情绪失调库存（EDI）。将利用患者报告的结果测量信息系统（PROMIS）项目和金标准统计方法的指南来完成EDI的校准和心理测量分析。主要样本将包括1000名儿童和年轻人的护理人员，这些儿童和年轻人来自社区，门诊和精神病患者的住院环境。数据收集将通过在线系统发生。分析将着重于建立EDI的因素结构/维度，发展不到10个项目的短形式，建立收敛性和不同的有效性，比较预期分数的EDI分数，例如，其分数将有所不同（例如，住院与社区样本与社区样本相比； ASD与健康对照组相比），并根据EDI的表现为跨越的EDI评分，并将表现为“ EDI相对于儿童的表现为情感上的情节”情节。精神病学单位。样本的一个子集将两次完成EDI，以建立重测可靠性。 EDI检测治疗变化的能力将通过比较稳定社区样本中专门研究ASD和4周变化分数的两个精神病患者单位的入院和提供者评级的EDI分数和出院。这项研究的主要结果将是一种用户友好的（例如在线，简短），经过验证的，治疗敏感的结果指标，用于与言语能力无关的ASD临床试验。此外，这项研究将产生他关于ASD中情绪失调的最大现有数据集，该数据将用于识别该人群中的情绪概况和治疗需求。在EDI中，挖掘个人情绪失调史的其他时间课程将对临床概念化有用，并有助于了解ASD和合并症精神疾病固有的情绪失调之间的界限。最后，对ASD中的情绪失调的敏感度量将有助于理解遗传和神经成像研究中的异质性，并将实现交叉人群研究